Your session is about to expire
← Back to Search
Other
ALTO-300 in Depression (ALTO-300-004)
Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 6 times over 8 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial studies ALTO-300, a treatment, to understand its effects on various patients. Researchers aim to find indicators that show how effective ALTO-300 is.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured 6 times over 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 6 times over 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-300
Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-300
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-300
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ALTO-300Experimental Treatment1 Intervention
ALTO-300 tablet PO; daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-300 PO Tablet
2022
Completed Phase 2
~150
Find a Location
Who is running the clinical trial?
Alto NeuroscienceLead Sponsor
10 Previous Clinical Trials
1,190 Total Patients Enrolled
9 Trials studying Depression
1,118 Patients Enrolled for Depression